Clinical trials: Thromboembolus
Deep Venous Thrombosis, Pulmonary Embolus
Real-time Anti-Factor Xa Measurements in Surgical Patients to Examine Enoxaparin Metabolism and Optimize Enoxaparin Dose
Venous thromboembolism (VTE) encompasses deep venous thrombosis and pulmonary embolus, and is the proximate cause of death in over 100,000 hospitalized patients per year.
- Conditions
- Deep Venous Thrombosis, Pulmonary Embolus, Venous Thromboembolism
- Trial name
- NCT02704052
- Testing
- Real time enoxaparin dose adjustment, Standard enoxaparin dose
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- University of Utah
Venous Thrombosis, Cardiovascular Diseases
Oral Anticoagulant Therapy for Venous Thrombosis - SCOR in Thrombosis
To perform a randomized clinical trial comparing continuing one month of treatment with heparin in patients with deep venous thrombosis to standard care using heparin for five days and oral warfarin for three months.
- Conditions
- Venous Thrombosis, Cardiovascular Diseases, Venous Thromboembolism
- Trial name
- NCT00005684
- Testing
- warfarin, heparin
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Cerebral Stroke, Thrombosis, Deep Vein
A Study of Adverse Events and Suspected Adverse Drug Reactions in Patients Under Apixaban for Prevention of Stroke and Systemic Embolism With Non-Valvular Atrial Fibrillation and Venous Thromboembolic Events in Patients Who Have Undergone Elective Hip or Knee Replacement Surgery
To characterize and analyze the number, type and incidence of adverse events/suspected adverse drug reactions in patients treated with Apixaban, according to therapeutic indications approved in Mexico.
- Conditions
- Cerebral Stroke, Thrombosis, Deep Vein, Pulmonary Embolism
- Trial name
- NCT03804125
- Sponsor
- Pfizer
Brain and Central Nervous System Tumors
Dalteparin and Radiation Therapy in Treating Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme
RATIONALE: Dalteparin may stop the growth of cancer by stopping blood flow to the tumor and by blocking the enzymes necessary for tumor cell growth. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00028678
- Testing
- dalteparin, radiation therapy
- Where
- 12 sites in United States
- Volunteers
- 45 people
- Sponsor
- Eastern Cooperative Oncology Group
Atrial Fibrillation
Evaluating the Use of SR34006 Compared to Warfarin or Acenocoumarol in Patients With Atrial Fibrillation (AMADEUS)
This trial will include patients who have a heart condition called atrial fibrillation. Atrial fibrillation is an abnormal rhythm (irregular beat) in the heart.
- Trial name
- NCT00070655
- Testing
- SR34006 (idraparinux sodium) Injection, vitamin K antagonist (warfarin or acenocoumarol) tablets
- Where
- 84 sites in United States, Australia and 8 more
- Volunteers
- 4,673 people
- Sponsor
- Sanofi
Prevention of Venous Thromboembolism
Rivaroxaban or Placebo for Extended Antithrombotic Prophylaxis After Laparoscopic Surgery for Colorectal Cancer.
Rivaroxaban or placebo for extended antithrombotic prophylaxis after laparoscopic surgery for colorectal cancer: a randomized, double blind, placebo-controlled study.
- Trial name
- PRO-LAPSII (NCT03055026)
- Testing
- Rivaroxaban
- Where
- 17 sites in Italy
- Volunteers
- 582 people
- Sponsor
- Fadoi Foundation, Italy
Antiphospholipid Syndrome, Venous Thromboembolism
Effectivity and Safety of Different Anticoagulants in Patients With Thromboembolic Antiphospholipid Syndrome
Retrospective monocentric registry to evaluate the efficacy and safety of different anticoagulants in patients with thromboembolic antiphospholipid syndrome
- Conditions
- Antiphospholipid Syndrome, Venous Thromboembolism, Arterial Thromboembolism, Major Bleed
- Trial name
- NCT05195372
- Where
- Germany
- Volunteers
- 80 people
- Sponsor
- Cardioangiologisches Centrum Bethanien
Anticoagulants, Atrial Fibrillation
Improving Anticoagulation Control in VISN 1
Over 100,000 VHA patients receive anticoagulants (blood thinners) each year to prevent blood clots (including strokes). Too much anticoagulation increases the risk of serious or even fatal bleeding, and too little anticoagulation…
- Conditions
- Anticoagulants, Atrial Fibrillation, Venous Thromboembolism
- Trial name
- NCT01653405
- Testing
- Multifaceted behavioral intervention
- Where
- United States
- Volunteers
- 1,260,576 people
- Sponsor
- VA Office of Research and Development
Circadian Variation in Anti-Factor Xa (Anti-FXa) Activity
Circadian Variation of Anti-Factor Xa in Hospitalized Trauma Patients
The purpose of this study is to determine whether a circadian rhythm exists in anti-FXa levels and AT3 activity in hospitalized trauma patients receiving low-molecular-weight heparin (LMWH) chemoprophylaxis
- Trial name
- NCT07856641
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- The University of Texas Health Science Center, Houston
Deep Venous Thrombosis, Upper Extremity Deep Venous Thrombosis
Apixaban for Routine Management of Upper Extremity Deep Venous Thrombosis
This study will assess the safety and effectiveness of a drug called apixaban for the treatment of upper extremity deep vein thrombosis (UEDVT) and clinically important bleeding.
- Conditions
- Deep Venous Thrombosis, Upper Extremity Deep Venous Thrombosis, Thrombus, Venous Thromboembolism
- Trial name
- ARM-DVT (NCT02945280)
- Testing
- apixaban
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Intermountain Health Care, Inc.
Cerebral Venous Thrombosis
Comparison of the Efficacy of Rivroxaban to Coumadin( Warfarin ) in Cerebral Venous Thrombosis
In past few years new anticoagulants have been developed which directly inhibit thrombin or factor X.factor x inhibitor is available in Pakistan.
- Trial name
- CVT (NCT03191305)
- Testing
- Coumadin, Rivoroxaban
- Volunteers
- 50 people
- Sponsor
- Foundation University Islamabad
Venous Thromboembolism, Deep-Vein Thrombosis
Pro-coagulant Markers and Anticoagulant Failure in Cancer Patients at Risk for Recurrence of Venous Thromboembolism
The presence of clots in the veins of arms and/or legs or lungs of Cancer patients decreases their quality of life, delays their treatment and may cause death.
- Conditions
- Venous Thromboembolism, Deep-Vein Thrombosis, Pulmonary Embolism, Cancer
- Trial name
- REMARK (NCT01602445)
- Where
- 5 sites in Canada
- Volunteers
- 700 people
- Sponsor
- Ottawa Hospital Research Institute
Cerebral Venous Thrombosis, Anticoagulants and Thrombotic Disorders
Safety and Efficacy of Edoxaban and Rivaroxaban to Cerebral Venous Thrombosis in Chinese Patients
The goal of this observational study is to learn the safety and efficacy of edoxaban and rivaroxaban in Chinese population with the age range from 18 to 80 years who take edoxaban or rivaroxaban to treat their cerebral venous…
- Conditions
- Cerebral Venous Thrombosis, Anticoagulants and Thrombotic Disorders, Anticoagulation Treatment, Anticoagulant Therapy
- Trial name
- NCT06947707
- Where
- China
- Volunteers
- 1,486 people
- Sponsor
- Xuanwu Hospital, Beijing
Pulmonary Embolism
Effect of a Global Simplified Strategy on Thromboembolic Events in Emergency Department Patients with Suspected Pulmonary Embolism
Pulmonary embolism (PE) is frequently suspected in emergency departments (ED) patients which often leads to the prescription of DDimer testing and irradiative chest imaging (Computed Tomographic Pulmonary Angiogram CTPA in most…
- Trial name
- MODS STRATEGY (NCT06190392)
- Testing
- MODS Modified simplified diagnostic strategy
- Where
- France
- Volunteers
- 1,223 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Venous Thromboembolism
Statin Use in Patients With Acute VTE
This is a pilot, randomized, open-labelled study. Eligible patients will be enrolled and randomized 1:1 into "anticoagulation" arm or "anticoagulation plus atorvastatin" arm, with atorvastatin given at 40 mg orally daily for 3…
- Trial name
- NCT02331095
- Testing
- Atorvastatin, Anticoagulation Therapy
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Ohio State University
Venous Thromboembolism, Deep Venous Thrombosis
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
This is a Phase 3, multicenter, open-label, blinded endpoint study to evaluate the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal…
- Conditions
- Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism
- Trial name
- MAGNOLIA (NCT05171075)
- Testing
- Abelacimab, Dalteparin
- Where
- 117 sites in United States, Australia and 18 more
- Volunteers
- 417 people
- Sponsor
- Anthos Therapeutics, Inc.
Venous Thromboembolism
Dalteparin vs Unfractionated Heparin For The Prevention Of Venous Thromboembolism (VTE) In Hospitalized Acutely Ill Medical Patients
The purpose of this study is to compare the efficacy and safety of dalteparin vs unfractionated heparin for the prevention of VTE (Venous Thromboembolism) in hospitalized acutely ill medical patients.
- Trial name
- NCT00445328
- Testing
- Dalteparin (Fragmin), Unfractionated heparin
- Where
- 7 sites in India
- Volunteers
- 84 people
- Sponsor
- Pfizer
Venous Thromboembolism, Deep Vein Thrombosis
Weight-Based Enoxaparin Dosing and Real-Time Dose Adjustment in Orthopaedic Trauma
The rates of Venous thromboembolism (VTE) after orthopedic surgery are as high as 40-60% without prophylactic measures. Enoxaparin, a low-molecular-weight heparin, produces an anticoagulant effect by binding antithrombin, thereby…
- Conditions
- Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolus
- Trial name
- NCT03339349
- Testing
- Enoxaparin
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Utah
Venous Thromboembolism, Pulmonary Embolism
Prediction of the COBRRA VTE Anticoagulant Trial in Healthcare Claims Data
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials.
- Conditions
- Venous Thromboembolism, Pulmonary Embolism, DVT
- Trial name
- NCT05264168
- Testing
- Rivaroxaban, Apixaban
- Where
- United States
- Volunteers
- 41,875 people
- Sponsor
- Brigham and Women's Hospital
Venous Thromboembolism
Replication of the RECOVER-II Anticoagulant Trial in Healthcare Claims Data
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials.
- Trial name
- NCT04735523
- Testing
- Dabigatran, Warfarin
- Where
- United States
- Volunteers
- 5,350 people
- Sponsor
- Brigham and Women's Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.